Methods, software, systems, and apparatuses that can identify bivalent reaction mechanisms using surface plasmon resonance (SPR) are provided. Methods, software, systems, and apparatuses that can identify SPR sensorgrams that fit a bivalent analyte model are also provided. A method can include recording multiple SPR sensorgrams with an analyte at different concentrations, fitting each sensorgram with a single exponential function with exponents, determining the exponents for each sensorgram and R.sup.2 values for each sensorgram, and plotting R.sup.2 versus analyte concentration and determining if an optimal concentration exists.

A computer-implemented method for determining minor variants. The method includes receiving electropherogram sequence data from a test sample, identifying any non-primary peaks in the electropherogram, and characterizing identified non-primary peaks using at least one signal feature. The method may further include analyzing the at least one signal feature across identified non-primary peaks to identify variant candidates, evaluating at least one peak characteristic of each of the identified variant candidates, and classifying variant candidates as bona fide variants based on the evaluation of peak characteristics.

In some embodiments, a device includes a memory and a processor. The memory is operatively coupled to the processor and configured to store encrypted personal data. The processor is configured to receive query and a personal identifier from a user. Based on the query, the processor further identifies and retrieves a portion of the associated encrypted personal data from the memory. Using the personal identifier, the processor produces decrypted personal data by decrypting a portion of the retrieved encrypted personal data. The processor is further configured to analyze the decrypted personal data to identify a result of the query. The result is sent to the user without sending the decrypted personal data.

Methods and systems for evaluating biological dataset profiles relating to inflammatory cardiovascular conditions are provided, where datasets comprising information for multiple cellular parameters are compared and identified, and used in the evaluation of candidate pharmacologic agents for suitability as therapeutic agents.

The present invention relates to a method for analyzing a sample. In particular, the present invention relates to a method for analyzing a sample and a method for correcting a raw data set of an amplification reaction. The present invention for analyzing a sample prevents from determining cycles based on false signals usually observed in a multitude of reactions and processes, thereby much more accurately obtaining information for analyzing a sample.

The invention is a diagnostic which overlays quantum mechanical analysis to x-ray crystallography data from one or more proteins to assess and identify the real world conformation, protonation and solvent effects of one or more moieties in said protein. This “overlay” occurs by scoring and identifying the protomer/tautomer states of the moieties using quantum mechanical analysis. The diagnostic results of the present invention accurately identify protein-ligand binding, rendered as an output to a user of a computer in which the x-ray crystallography data is analysed with semi-empirical Hamiltonian quantum mechanics and

The present invention provides a method for evaluating (predicting, etc.) an individual difference (the tendency of every individual) in terms of drug sensitivity and disease vulnerability, comprising using a gene polymorphism of a cyclic AMP responsive element binding protein gene or the like. The method for evaluating drug sensitivity and the method for evaluating disease vulnerability according to the present invention comprise associating a gene polymorphism of a cyclic AMP responsive element binding protein gene or a haplotype constituted by the gene polymorphism with the drug sensitivity and disease vulnerability of an individual.

A computer-implemented method for processing and/or analyzing nucleic acid sequencing data comprises receiving a first data input and a second data input. The first data input comprises untargeted sequencing data generated from a first nucleic acid sample obtained from a subject. The second data input comprises target-specific sequencing data generated from a second nucleic acid sample obtained from the subject. Next, with the aid of a computer processor, the first data input and the second data input are combined to produce a combined data set. Next, an output derived from the combined data set is generated. The output is indicative of the presence or absence of one or more polymorphisms of the first nucleic acid sample and/or the second nucleic acid sample.

The invention encompasses products and methods relating to microRNAs involved in various cancers.

The present technology encompasses systems for predicting a characteristic of an individual subject, as well as methods for predicting a characteristic of a particular subject based on the systems of the technology disclosed herein. The disclosure herein also provides methods to improve a characteristics in a subject, based on the prediction produced by the system.